Menopause and diabetes

References

• Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.
   PubMed Web of Science ®Google Scholar
• Toth MJ, Tchernof A, Sites CK, et al. Effect of menopausal status on body composition and abdominal fat distribution. Int J Obes. 2000;24(2):226–231.
   PubMed Web of Science ®Google Scholar
• Tserotas K, Blumel JE. Menopause research in Latin America. Climacteric. 2019;22(1):17–21.
   PubMed Web of Science ®Google Scholar
• Pu D, Tan R, Yu Q, et al. Metabolic syndrome in menopause and associated factors: a meta-analysis. Climacteric. 2017;20(6):583–591.
   PubMed Web of Science ®Google Scholar
• Mauvais-Jarvis F, Manson JE, Stevenson JC, et al. Menopausal hormone therapy and type 2 diabetes prevention: evidence, mechanisms, and clinical implications. Endocr Rev. 2017;38(3):173–188.
   PubMed Web of Science ®Google Scholar
• Lovejoy JC, Champagne CM, de Jonge L, et al. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes. 2008;32(6):949–958.
   Web of Science ®Google Scholar
• Rogers NH, Perfield JW, Strissel KJ, et al. Reduced energy expenditure and increased inflammation are early events in the development of ovariectomy-induced obesity. Endocrinology. 2009;150(5):2161–2168.
   PubMed Web of Science ®Google Scholar
• Paschou SA, Anagnostis P, Goulis DG, et al. Androgen excess and post-reproductive health. Maturitas. 2018;115:115–116.
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Monteleone P, Giannini A, et al. Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice. Hum Reprod Update. 2021;18:1115–1150.
   Google Scholar
• Santoro N, Sutton-Tyrrell K. The SWAN song: study of women’s health across the nation’s recurring themes. Obstet Gynecol Clin North Am. 2011;38(3):417–423.
   PubMed Web of Science ®Google Scholar
• Davis SR, Castelo-Branco C, Chedraui P, et al. Writing group of the international menopause society for world menopause day 2012: understanding weight gain at menopause. Climacteric. 2012;15(5):419–429.
   PubMed Web of Science ®Google Scholar
• Blümel JE, Fica J, Chedraui P, et al. Collaborative group for research of the climacteric in Latin America. Sedentary lifestyle in middle-aged women is associated with severe menopausal symptoms and obesity. Menopause. 2016;23(5):488–493.
   PubMed Web of Science ®Google Scholar
• Li W, Wang Y, Shen L, et al. Association between parity and obesity patterns in a middle-aged and older Chinese population: a cross-sectional analysis in the Tongji-Dongfeng cohort study. Nutr Metab. 2016;26:13,72.
   Google Scholar
• Bouchard C. Genetics of obesity: What we have learned over decades of research. Obesity. 2021;29(5):802–820.
   PubMed Web of Science ®Google Scholar
• Kravitz HM, Kazlauskaite R, Joffe H. Sleep, health, and metabolism in midlife women and menopause: food for thought. Obstet Gynecol Clin North Am. 2018;45(4):679–694.
   PubMed Web of Science ®Google Scholar
• Verhaegen AA, Van Gaal LF. Drugs affecting body weight, body fat distribution, and metabolic function-mechanisms and possible therapeutic or preventive measures: an update. Curr Obes Rep. 2021;10(1):1–13.
   PubMed Web of Science ®Google Scholar
• Monterrosa-Castro A, Blümel JE, Portela-Buelvas K, et al. Collaborative group for research of the climacteric in Latin America (REDLINC). Type II diabetes mellitus and menopause: a multinational study. Climacteric. 2013;16:663–672.
   PubMed Web of Science ®Google Scholar
• Matthews KA, Gibson CJ, El Khoudary SR, et al. Changes in cardiovascular risk factors by hysterectomy status with and without oophorectomy: study of women’s health across the nation. J Am Coll Cardiol. 2013;16:191–200.
   Google Scholar
• Park SK, Harlow SD, Zheng H, et al. Association between changes in oestradiol and follicle‐stimulating hormone levels during the menopausal transition and risk of diabetes. Diabet Med. 2017;34(4):531–538.
   PubMed Web of Science ®Google Scholar
• Brand JS, van der Schouw YT, Onland-Moret NC, et al. The InterAct consortium. age at menopause, reproductive life span, and type 2 diabetes risk: results from the EPIC-InterAct study. Diabetes Care. 2013;36(4):1012–1019.
   PubMed Web of Science ®Google Scholar
• Anagnostis P, Christou K, Artzouchaltzi AM, et al. Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis. Eur J Endocrinol. 2019;1:41–50.
   Google Scholar
• Shen L, Song L, Li H, et al. Association between earlier age at natural menopause and risk of diabetes in middle-aged and older Chinese women: the Dongfeng-Tongji cohort study. Diabetes Metab. 2017;43(4):345–350.
   PubMed Web of Science ®Google Scholar
• Appiah D, J. Winters JS, Hornung CA. Bilateral oophorectomy and the risk of incident diabetes in postmenopausal women. Diabetes Care. 2014;37(3):725–733.
   PubMed Web of Science ®Google Scholar
• LeBlanc ES, Kapphahn K, Hedlin H, et al. Reproductive history and risk of type 2 diabetes mellitus in postmenopausal women: findings from the women’s health initiative. Menopause. 2017;24(1):64–72.
   PubMed Web of Science ®Google Scholar
• Wang M, Gan W, Kartsonaki C, et al. Menopausal status, age at natural menopause and risk of diabetes in China: a 10-year prospective study of 300,000 women. Nutr Metab. 2022;19(1):7.
   Google Scholar
• Dorman JS, Steenkiste AR, Foley TP, et al. Menopause in type 1 diabetic women: Is it premature? Diabetes. 2001;50(8):1857–1862.
   PubMed Web of Science ®Google Scholar
• Brand JS, Onland-Moret NC, Eijkemans MJ, et al. Diabetes and onset of natural menopause: results from the European prospective investigation into cancer and nutrition. Hum Reprod. 2015;30(6):1491–1498.
   PubMed Web of Science ®Google Scholar
• Yarde F, Van Der Schouw YT, de Valk HW, et al. Age at menopause in women with type 1 diabetes mellitus: the OVADIA study. Hum Reprod. 2015;30:441–446.
   PubMed Web of Science ®Google Scholar
• Kim C, Cleary PA, Cowie CC, et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) cohort. Diabetes Care. 2014;37(3):701–708.
   PubMed Web of Science ®Google Scholar
• Sjöberg L, Pitkäniemi J, Harjutsalo V, et al. Menopause in women with type 1 diabetes. Menopause. 2011;18(2):158–163.
   PubMed Web of Science ®Google Scholar
• Stuenkel CA. Menopause, hormone therapy and diabetes. Climacteric. 2017;20(1):11–21.
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez R, Huerta R, Malacara JM. Age at menopause in women with type 2 diabetes mellitus. Menopause. 1999;6:174–178.
   PubMed Web of Science ®Google Scholar
• Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the heart and Estrogen/progestin replacement study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138(1):1–9.
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Walsh JM, Ormiston TM, et al. Meta‐analysis: effect of hormone‐replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006;8(5):538–554.
   PubMed Web of Science ®Google Scholar
• Anagnostis P, Galanis P, Chatzistergiou V, et al. The effect of hormone replacement therapy and tibolone on lipoprotein(a) concentrations in postmenopausal women: a systematic review and meta-analysis. Maturitas. 2017;99:27–36.
   PubMed Web of Science ®Google Scholar
• Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the women’s health initiative hormone trial. Diabetologia. 2004;47(7):1175–1187.
   PubMed Web of Science ®Google Scholar
• Manson JE, Rimm EB, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. Ann Epidemiol. 1992;2(5):665–673.
   PubMedGoogle Scholar
• de Lauzon-Guillain B, Fournier A, Fabre A, et al. Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Générale de l‘Education Nationale (E3N) cohort. Diabetologia. 2009;52(10):2092–2100.
   PubMed Web of Science ®Google Scholar
• Duncan AC, Lyall H, Roberts RN, et al. The effect of estradiol and a combined estradiol/progestagen preparation on insulin sensitivity in healthy postmenopausal women. J Clin Endocrinol Metab. 1999;84(7):2402–2407.
   PubMed Web of Science ®Google Scholar
• Mauvais-Jarvis F. Role of sex steroids in β cell function, growth, and survival. Trends Endocrinol Metab. 2016;27(12):844–855.
   PubMed Web of Science ®Google Scholar
• Gray KE, Katon JG, LeBlanc ES, et al. Vasomotor symptom characteristics: are they risk factors for incident diabetes? Menopause. 2018;25(5):520–530.
   PubMed Web of Science ®Google Scholar
• Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women–2011 update: a guideline from the American heart association. Circulation. 2011;123(11):1243–1262.
   PubMedGoogle Scholar
• Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–234.
   PubMed Web of Science ®Google Scholar
• Howard BV, Best LG, Galloway JM, et al. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care. 2006;29(2):391–397.
   PubMed Web of Science ®Google Scholar
• Bulugahapitiya U, Siyambalapitiya S, Sithole J, et al. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med. 2009;26(2):142–148.
   PubMed Web of Science ®Google Scholar
• US Preventive Services Task Force. Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: US preventive services task force recommendation statement. JAMA. 2022;328:1740–1746.
   PubMed Web of Science ®Google Scholar
• Langer RD, Simon JA, Pines A, et al. Menopausal hormone therapy for primary prevention: Why the USPSTF is wrong. Climacteric. 2017;20(5):402–413.
   PubMed Web of Science ®Google Scholar
• Pan M, Pan X, Zhou J, et al. Update on hormone therapy for the management of postmenopausal women. Biosci Trends. 2022;16(1):46–57.
   PubMed Web of Science ®Google Scholar
• Baber RJ, Panay N, Fenton A. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150.
   PubMed Web of Science ®Google Scholar
• The 2022 hormone therapy position statement of the North American menopause society. Menopause. 2022;29:767–794.
   PubMed Web of Science ®Google Scholar
• Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol. 1982;144(5):511–518.
   PubMed Web of Science ®Google Scholar
• Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev. 2013;34(3):309–338.
   PubMed Web of Science ®Google Scholar
• Elkik F, Gompel A, Mercier-Bodard C, et al. Effects of percutaneous estradiol and conjugated estrogens on the level of plasma proteins and triglycerides in postmenopausal women. Am J Obstet Gynecol. 1982;143(8):888–892.
   PubMed Web of Science ®Google Scholar
• Slopien R, Wender-Ozegowska E, Rogowicz-Frontczak A, et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018;117:6–10.
   PubMed Web of Science ®Google Scholar
• El Sayed NA, Aleppo G, Aroda VR, et al. Summary of revisions: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S5–S9.
   PubMedGoogle Scholar